Insider Selling: Bicycle Therapeutics (NASDAQ:BCYC) Director Sells $11,905.57 in Stock

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Director Robert Swanton sold 3,431 shares of the company’s stock in a transaction that occurred on Friday, October 2nd. The shares were sold at an average price of $3.47, for a total value of $11,905.57. Following the completion of the sale, the director owned 15,782 shares in the company, valued at approximately $54,763.54. This represents a 17.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Bicycle Therapeutics Price Performance

Bicycle Therapeutics stock opened at $3.81 on Friday. The company has a market capitalization of $266.67 million, a PE ratio of -1.40 and a beta of 1.68. Bicycle Therapeutics PLC Sponsored ADR has a one year low of $3.33 and a one year high of $9.16. The business has a 50 day simple moving average of $3.96 and a 200 day simple moving average of $4.29.

Bicycle Therapeutics (NASDAQ:BCYC) last announced its quarterly earnings results on Thursday, July 30th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.14). Bicycle Therapeutics had a negative net margin of 311.11% and a negative return on equity of 33.22%. The company had revenue of $0.63 million during the quarter, compared to analyst estimates of $4.22 million. Equities analysts anticipate that Bicycle Therapeutics PLC Sponsored ADR will post -2.26 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Bicycle Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Portland Investment Counsel Inc. acquired a new stake in Bicycle Therapeutics in the second quarter worth about $64,000. Marquette Asset Management LLC acquired a new position in Bicycle Therapeutics during the 2nd quarter valued at about $309,000. FNY Investment Advisers LLC boosted its stake in shares of Bicycle Therapeutics by 247.4% in the 2nd quarter. FNY Investment Advisers LLC now owns 26,250 shares of the company’s stock valued at $111,000 after purchasing an additional 18,693 shares during the last quarter. GAMMA Investing LLC grew its position in shares of Bicycle Therapeutics by 512.9% during the 2nd quarter. GAMMA Investing LLC now owns 7,704 shares of the company’s stock worth $33,000 after buying an additional 6,447 shares during the period. Finally, Flax Pond Capital LLC grew its position in shares of Bicycle Therapeutics by 1.4% during the 1st quarter. Flax Pond Capital LLC now owns 176,136 shares of the company’s stock worth $817,000 after buying an additional 2,503 shares during the period. Institutional investors own 86.15% of the company’s stock.

Analysts Set New Price Targets

BCYC has been the topic of several analyst reports. Wall Street Zen raised shares of Bicycle Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, August 15th. Weiss Ratings restated a “sell (e+)” rating on shares of Bicycle Therapeutics in a research report on Friday, October 2nd. Finally, Needham & Company LLC decreased their price objective on shares of Bicycle Therapeutics from $15.00 to $14.00 and set a “buy” rating on the stock in a research note on Thursday, July 30th. Five equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $13.86.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc (NASDAQ:BCYC) is a clinical-stage biotechnology company developing medicines based on its proprietary Bicycle molecule platform. The platform uses short, chemically constrained peptides designed to bind selectively to biological targets, with the goal of combining the tissue penetration and target specificity of small molecules with some of the binding characteristics of larger biologic medicines.

The company is focused primarily on oncology and is developing Bicycle toxin conjugates, immune-cell engaging molecules and other targeted therapeutics.